[
  {
    "ts": null,
    "headline": "Cantor Fitzgerald Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "summary": "Cantor Fitzgerald Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=8a318fa2c389b1828820959bf253938401f8c23ad42f752759bb906008ccb636",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761952665,
      "headline": "Cantor Fitzgerald Maintains Eli Lilly and (LLY) Overweight Recommendation",
      "id": 137283059,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8a318fa2c389b1828820959bf253938401f8c23ad42f752759bb906008ccb636"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Week Ahead: October Marks A 7-Year Best For The Nasdaq",
    "summary": "After the Nasdaq sets a seven-year record, a slew of high flying stocks report in the coming week. Plus there's a bonus day from Tesla.",
    "url": "https://finnhub.io/api/news?id=a4608bc48006da8955639b7287cf78b3eb12d875fdae26c2c1202eb68f64a663",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761947691,
      "headline": "Stock Market Week Ahead: October Marks A 7-Year Best For The Nasdaq",
      "id": 137294504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After the Nasdaq sets a seven-year record, a slew of high flying stocks report in the coming week. Plus there's a bonus day from Tesla.",
      "url": "https://finnhub.io/api/news?id=a4608bc48006da8955639b7287cf78b3eb12d875fdae26c2c1202eb68f64a663"
    }
  },
  {
    "ts": null,
    "headline": "Busy earnings week recap: 'It's all looking pretty positive'",
    "summary": "BD8 Capital Partners CEO and CIO, Barbara Doran, joins Market Domination host Josh Lipton to discuss the biggest earnings results that were posted this week, artificial intelligence (AI) demand, and her top three stock picks. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=07640635ef29d2c05654242d2c14641cd2497c559a26fadf5b2854eaef647ba4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761946200,
      "headline": "Busy earnings week recap: 'It's all looking pretty positive'",
      "id": 137294505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BD8 Capital Partners CEO and CIO, Barbara Doran, joins Market Domination host Josh Lipton to discuss the biggest earnings results that were posted this week, artificial intelligence (AI) demand, and her top three stock picks. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=07640635ef29d2c05654242d2c14641cd2497c559a26fadf5b2854eaef647ba4"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple pares gains with earnings from AI players to come",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=f71dd7ce2ec6ef6631512e643d8937c9c24821909027b57a9fe612fd64a8afb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761945147,
      "headline": "Earnings live: Amazon stock soars, Apple pares gains with earnings from AI players to come",
      "id": 137282600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=f71dd7ce2ec6ef6631512e643d8937c9c24821909027b57a9fe612fd64a8afb5"
    }
  },
  {
    "ts": null,
    "headline": "Evaluating Eli Lilly (LLY): Is the Pharma Giant’s Recent Growth Reflected in Its Current Valuation?",
    "summary": "Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors interested in healthcare stocks may be taking note of its consistent growth, especially as momentum in the biotech sector picks up. See our latest analysis for Eli Lilly. Eli Lilly’s share price recently surged 10.7% over the past month, a move that has added to its solid year-to-date momentum. While the 1-year total shareholder return stands at just 2.6%, the...",
    "url": "https://finnhub.io/api/news?id=7f5695c6aba537207f90c7415cca57d49a096557ecb1a75748ef2fabaaf5e430",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761942067,
      "headline": "Evaluating Eli Lilly (LLY): Is the Pharma Giant’s Recent Growth Reflected in Its Current Valuation?",
      "id": 137294507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors interested in healthcare stocks may be taking note of its consistent growth, especially as momentum in the biotech sector picks up. See our latest analysis for Eli Lilly. Eli Lilly’s share price recently surged 10.7% over the past month, a move that has added to its solid year-to-date momentum. While the 1-year total shareholder return stands at just 2.6%, the...",
      "url": "https://finnhub.io/api/news?id=7f5695c6aba537207f90c7415cca57d49a096557ecb1a75748ef2fabaaf5e430"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly is making weight-loss pills before regulatory approval",
    "summary": "Eli Lilly (LLY) is producing weight-loss pills ahead of US approval to prepare inventory for when the product enters the market. Eli Lilly CFO Lucas Montarce talks to Yahoo Finance about Eli Lilly's expectations for the drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=1cd4b2b5a3a3eac7276fb527ab67b483a9da5b223e389e2b0590ea3e5fe984b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761928222,
      "headline": "Why Eli Lilly is making weight-loss pills before regulatory approval",
      "id": 137279021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is producing weight-loss pills ahead of US approval to prepare inventory for when the product enters the market. Eli Lilly CFO Lucas Montarce talks to Yahoo Finance about Eli Lilly's expectations for the drug. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=1cd4b2b5a3a3eac7276fb527ab67b483a9da5b223e389e2b0590ea3e5fe984b3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Solid Q3 Highlights Strong Mounjaro Demand; Orforglipron Launch in 2026 Seen as Growth Driver, Morgan Stanley Says",
    "summary": "Eli Lilly (LLY) delivered another solid quarter, citing strong international demand for type 2 diabe",
    "url": "https://finnhub.io/api/news?id=380a075d714609cda7e0cf60a2af154883748c417c2b513c9655aca3015fee9e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761922839,
      "headline": "Eli Lilly's Solid Q3 Highlights Strong Mounjaro Demand; Orforglipron Launch in 2026 Seen as Growth Driver, Morgan Stanley Says",
      "id": 137279022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) delivered another solid quarter, citing strong international demand for type 2 diabe",
      "url": "https://finnhub.io/api/news?id=380a075d714609cda7e0cf60a2af154883748c417c2b513c9655aca3015fee9e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs",
    "summary": "STORY: :: Novo Nordisk Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.That’s according to a LinkedIn post by CEO Mike Doustdar Friday. As jobs were slashed globally, he added that the pace of informing people varied according to local laws. It’s part of Doustdar’s restructuring drive which he launched last month. And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  :: Pfizer The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. The drugmakers are vying for access to its once-monthly GLP-1 injectable.Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. Metsera is one of several companies developing experimental weight-loss drugs.The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.That was over concerns it was not moving fast enough in the obesity market.",
    "url": "https://finnhub.io/api/news?id=038c78804c817adcd3cd069084a2da429170bd73fb73930a95fcc97e4b7a5cc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761920886,
      "headline": "Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs",
      "id": 137279023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: :: Novo Nordisk Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.That’s according to a LinkedIn post by CEO Mike Doustdar Friday. As jobs were slashed globally, he added that the pace of informing people varied according to local laws. It’s part of Doustdar’s restructuring drive which he launched last month. And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  :: Pfizer The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. The drugmakers are vying for access to its once-monthly GLP-1 injectable.Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. Metsera is one of several companies developing experimental weight-loss drugs.The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.That was over concerns it was not moving fast enough in the obesity market.",
      "url": "https://finnhub.io/api/news?id=038c78804c817adcd3cd069084a2da429170bd73fb73930a95fcc97e4b7a5cc1"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Oct 31, 2025",
    "summary": "Companies in The News Are: WDC,LLY,IP,CAH",
    "url": "https://finnhub.io/api/news?id=ef57abef46bbc3a48bbf815243f9790c534f331f5a9a56f601983c88bbad1b64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761918120,
      "headline": "Company News for Oct 31, 2025",
      "id": 137279024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies in The News Are: WDC,LLY,IP,CAH",
      "url": "https://finnhub.io/api/news?id=ef57abef46bbc3a48bbf815243f9790c534f331f5a9a56f601983c88bbad1b64"
    }
  },
  {
    "ts": null,
    "headline": "Massive sales for weight loss drugs spur Eli Lilly’s Q3",
    "summary": "Mounjaro and Zepbound sales fuelled Eli Lilly’s strong Q3, which surpassed analyst forecasts.",
    "url": "https://finnhub.io/api/news?id=71880cc09f38efad6c8a19542c07f9994ddc33af23d19e6cb04ed5f825cc4f37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761912214,
      "headline": "Massive sales for weight loss drugs spur Eli Lilly’s Q3",
      "id": 137277247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mounjaro and Zepbound sales fuelled Eli Lilly’s strong Q3, which surpassed analyst forecasts.",
      "url": "https://finnhub.io/api/news?id=71880cc09f38efad6c8a19542c07f9994ddc33af23d19e6cb04ed5f825cc4f37"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise, Techs Jump As Amazon, Apple Lead Earnings Winners",
    "summary": "Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.",
    "url": "https://finnhub.io/api/news?id=473203bdf7dcbb4f7a2e47f28a4b6f2f6dbccdb59ffc82f46aea608373a3fb3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761912153,
      "headline": "Dow Jones Futures Rise, Techs Jump As Amazon, Apple Lead Earnings Winners",
      "id": 137277142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.",
      "url": "https://finnhub.io/api/news?id=473203bdf7dcbb4f7a2e47f28a4b6f2f6dbccdb59ffc82f46aea608373a3fb3b"
    }
  },
  {
    "ts": null,
    "headline": "Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma",
    "summary": "Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Desmoid Tumors Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.One of the key drivers of the Desmoid Tumors market is the advancement of targeted therapies. As the understanding of the molecular and genetic drivers of Desmoid Tumors improves, companies are developing more precise, personalized treatments that target the specific pathways invo",
    "url": "https://finnhub.io/api/news?id=97e0d410252f4f66c945885cae5e873bac1db87bc8e9b35c6307ccabc575b470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911760,
      "headline": "Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma",
      "id": 137277249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The \"Desmoid Tumors Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.One of the key drivers of the Desmoid Tumors market is the advancement of targeted therapies. As the understanding of the molecular and genetic drivers of Desmoid Tumors improves, companies are developing more precise, personalized treatments that target the specific pathways invo",
      "url": "https://finnhub.io/api/news?id=97e0d410252f4f66c945885cae5e873bac1db87bc8e9b35c6307ccabc575b470"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=0d374a6f615b03923a5b1906860ea67364e16f6df8733aae70ff5a55b47aac48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911406,
      "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' quarter; Exxon, Chevron post strong earnings",
      "id": 137277110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=0d374a6f615b03923a5b1906860ea67364e16f6df8733aae70ff5a55b47aac48"
    }
  },
  {
    "ts": null,
    "headline": "Lilly quietly cuts a pain drug from its pipeline",
    "summary": "The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company’s \"high internal bar for success,\" a spokesperson said.",
    "url": "https://finnhub.io/api/news?id=c87f0c45458b88ae98cf615f001ae158ed714b1b4708632278863da2d4ff922f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761911280,
      "headline": "Lilly quietly cuts a pain drug from its pipeline",
      "id": 137279025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company’s \"high internal bar for success,\" a spokesperson said.",
      "url": "https://finnhub.io/api/news?id=c87f0c45458b88ae98cf615f001ae158ed714b1b4708632278863da2d4ff922f"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761908940,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137277251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=26dc2c19b37ba30da6680c5ed9fbf7d620da5631680a2c31444648b7d8378f8c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Has A Solid Upside Now After Its Q3 Earnings",
    "summary": "Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. Learn more about LLY stock here.",
    "url": "https://finnhub.io/api/news?id=2995f6c8f29b0420b1fd2df8dbf0ab5a238810d16c4b80e76735a15cb2382c3c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761907940,
      "headline": "Eli Lilly Has A Solid Upside Now After Its Q3 Earnings",
      "id": 137277842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2157849824/image_2157849824.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. Learn more about LLY stock here.",
      "url": "https://finnhub.io/api/news?id=2995f6c8f29b0420b1fd2df8dbf0ab5a238810d16c4b80e76735a15cb2382c3c"
    }
  },
  {
    "ts": null,
    "headline": "Weekly Recap: 12 Tech Press Releases You Need to See",
    "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
    "url": "https://finnhub.io/api/news?id=fc7820b5707fde4e5b87a8512350c79316db23e0aadb5273ca8f070f6af91f1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761907320,
      "headline": "Weekly Recap: 12 Tech Press Releases You Need to See",
      "id": 137277209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
      "url": "https://finnhub.io/api/news?id=fc7820b5707fde4e5b87a8512350c79316db23e0aadb5273ca8f070f6af91f1e"
    }
  },
  {
    "ts": null,
    "headline": "Corporate venture firms stepped in for drug startups during biotech funding pullback",
    "summary": "According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.",
    "url": "https://finnhub.io/api/news?id=bf177f1ad6c2c93c26bc80b8fd943ce1f70ca7909ff07f0dae7888423fb3382a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761893100,
      "headline": "Corporate venture firms stepped in for drug startups during biotech funding pullback",
      "id": 137277253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.",
      "url": "https://finnhub.io/api/news?id=bf177f1ad6c2c93c26bc80b8fd943ce1f70ca7909ff07f0dae7888423fb3382a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.",
    "summary": "The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug market.",
    "url": "https://finnhub.io/api/news?id=37eebaa4148b6f05c556a1ee59aa1bae465480cf00ca1bb1c25a5b1775f50bf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761888600,
      "headline": "Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain.",
      "id": 137274975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug market.",
      "url": "https://finnhub.io/api/news?id=37eebaa4148b6f05c556a1ee59aa1bae465480cf00ca1bb1c25a5b1775f50bf2"
    }
  },
  {
    "ts": null,
    "headline": "1 Healthcare Stock with Impressive Fundamentals and 2 We Ignore",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 9.8% gain for healthcare stocks has fallen short of the S&P 500’s 22.6% rise.",
    "url": "https://finnhub.io/api/news?id=2d89d911f0946c81efd72a80b0ccb37e68cad18846e03d0c2517ccb0f3b15f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761885616,
      "headline": "1 Healthcare Stock with Impressive Fundamentals and 2 We Ignore",
      "id": 137274976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 9.8% gain for healthcare stocks has fallen short of the S&P 500’s 22.6% rise.",
      "url": "https://finnhub.io/api/news?id=2d89d911f0946c81efd72a80b0ccb37e68cad18846e03d0c2517ccb0f3b15f38"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Amazon, Apple Earnings Lift Techs After Meta-Led Market Slide",
    "summary": "Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.",
    "url": "https://finnhub.io/api/news?id=92ca71c16142719d643ba3b24e0075f74b2b189365503dcd0b08a7e9af1f13dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761879422,
      "headline": "Dow Jones Futures: Amazon, Apple Earnings Lift Techs After Meta-Led Market Slide",
      "id": 137274869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tech futures rose on Amazon, Apple and other earnings winners late after Meta led stocks lower Thursday.",
      "url": "https://finnhub.io/api/news?id=92ca71c16142719d643ba3b24e0075f74b2b189365503dcd0b08a7e9af1f13dd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Co (LLY) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...",
    "summary": "Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic growth initiatives.",
    "url": "https://finnhub.io/api/news?id=00406e66c081c95356450ce8fd8006f448f5c14e8fdc015886ea92a765d0d406",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761872747,
      "headline": "Eli Lilly and Co (LLY) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...",
      "id": 137274978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic growth initiatives.",
      "url": "https://finnhub.io/api/news?id=00406e66c081c95356450ce8fd8006f448f5c14e8fdc015886ea92a765d0d406"
    }
  }
]